Two programmes created in the early 1990s with the intention of helping consumers pay for their prescribed medications are expected to expand substantially in 2024.
Just days after the US presidential race officially narrowed to a contest between President Joe Biden and former president Donald Trump, it’s no surprise that Biden’s State of the Union spe
Drug pricing in the US is a perennial topic, which is no surprise given the the US spends more per capita on prescription medicines than any other country.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh